Medical Research News

RSS

Understanding mitochondrial biology in alcohol-associated liver disease and cancer

For decades, giant mitochondria-known as megamitochondria-have been recognized in liver biopsies from patients with alcohol-associated liver disease (ALD).

1 Jun 2026

Healthy lifestyles reduce cardiovascular risks for childhood cancer survivors

Healthy lifestyles can reduce the risk of cardiovascular disease and other complications in childhood cancer survivors.

1 Jun 2026

Post-discharge oral antibiotics show no benefit for pediatric appendicitis

Acute appendicitis is one of the most common surgical emergencies among children, and complicated acute appendicitis (CAA), including perforated or gangrenous disease, carries a higher risk of infection and longer hospitalization.

1 Jun 2026

Moderate-to-vigorous physical activity boosts middle-age mental health more than walking

Moderate-to-vigorous physical activity is more important for mental health in middle age than light physical activity, according to a new study by the University of Oulu and ODL Department of Sports and Exercise Medicine.

1 Jun 2026

Weight loss drugs could widen health inequalities without nutritional support

Drugs such as semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro) are transforming obesity treatment, but without affordable, healthy food and appropriate support, they could widen health inequalities in the UK, according to researchers at UCL and the University of Cambridge.

1 Jun 2026

Bariatric surgery improves long-term ability to manage household tasks

People who undergo bariatric surgery and see substantial weight loss are better able to cope with household tasks such as cleaning, laundry and grocery shopping.

1 Jun 2026

Laverock Therapeutics awarded in excess of £2.2 M through two innovation grants to support AI-powered platform development and to expand therapeutic programs outside of oncology

Laverock Therapeutics ('Laverock'), a biotechnology company developing disease-responsive advanced therapies through its unique, programmable gene control technology, today announced it has been awarded two new grants totaling in excess of £2.2 M to support the next generation of its gene-control platform development, and expansion into additional non-oncology therapeutics areas.

From Laverock Therapeutics 1 Jun 2026

Pharmacist-led care delivering real results for women’s health

Pharmacy Guild of Australia, NSW Branch, today welcomed the release of new data from two NSW Government-sponsored clinical trials confirming allowing pharmacists to diagnose and treat uncomplicated urinary tract infections (UTIs) and providing resupply of oral contraception is delivering safe, effective care for women, while easing pressure on the health system and saving emergency departments millions of dollars.

1 Jun 2026

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships.

From Hanson Wade Group - 4th Nasal Formulation & Delivery Summit 1 Jun 2026

Apple Watch app detects seizures with 98% accuracy

The EpiWatch app shows high sensitivity in detecting tonic-clonic seizures in children and adults, potentially reducing SUDEP risk with timely alerts.

1 Jun 2026

Health workers face hidden exposure to cancer-linked hazards

A study reveals high exposure to cancer risk factors among health and social care workers in Europe, underscoring the need for enhanced protective measures.

1 Jun 2026

Lower Alzheimer’s amyloid levels in Black and Latinx adults

Findings show lower amyloid PET positivity in Black and Latinx adults with cognitive impairment, highlighting disparities in dementia diagnosis and treatment.

1 Jun 2026

Justicia carnea extract alleviates oxidative stress in pancreatitis

Chronic pancreatitis is an inflammatory disease and is difficult to manage despite advancements in medical science.

1 Jun 2026

Hypoxia-gated AAV enables targeted treatment for advanced NSCLC

Adeno‑associated virus (AAV) vectors offer safety and durable expression but lack tumor specificity. This hypothesis proposes an NSCLC‑directed, hypoxia‑responsive AAV platform that integrates MGS4 peptide‑guided capsid targeting with dual hypoxia‑responsive element (HRE)‑gated promoters driving Q‑CXCL9‑Fc (chemokine) and miR‑30‑based shRNA against mesothelin (MSLN).

1 Jun 2026

Mesenchymal drift may explain how aging cells lose their identity

Mesenchymal drift may help explain how cells lose stable identity and acquire pro-fibrotic, inflammatory mesenchymal traits during aging. The review proposes MD as a unifying framework that links multiple hallmarks of aging and highlights partial reprogramming as a potential, but still preclinical, way to counteract this process.

1 Jun 2026

New T-cell engager therapy shows effectiveness in advanced solid tumors

A team led by researchers from the National Center for Tumor Diseases (NCT/UCC) Dresden at the Carl Gustav Carus University Hospital (UKD) and the Carl Gustav Carus Faculty of Medicine at the TUD Dresden University of Technology will present clinical results for the first time on May 31, 2026, at this year’s annual meeting of the American Society of Clinical Oncology (ASCO) regarding a new cancer immunotherapy for the treatment of advanced tumors.

1 Jun 2026

The right seafood choices can help diets meet health and climate goals

Fish can support healthy and sustainable diets, especially when it replaces red and processed meat rather than adding to overall animal-food intake. However, its environmental value depends on species, production system, supply chain, local dietary patterns, and the scale of greenhouse gas reductions required.

1 Jun 2026

Higher-dose ocrelizumab depletes more B cells but does not slow MS progression

Higher-dose ocrelizumab produced greater peripheral B-cell depletion than the approved 600 mg regimen in two phase 3b trials of relapsing and primary progressive multiple sclerosis. However, the higher doses did not significantly delay disability progression, supporting the 600 mg dose as the current standard regimen with a favorable benefit-risk profile.

31 May 2026

Why new Alzheimer’s drugs are dividing regulators worldwide

The Lancet World Report examines why regulators in the US, UK, and Europe have reached different decisions on new amyloid-targeting Alzheimer’s drugs despite evidence that they can modestly slow clinical decline. It highlights the unresolved balance among benefits, safety risks, costs, access, and the need for broader, earlier, and more patient-centered treatment strategies.

31 May 2026